Since unexpected sudden deaths have been reported with the use of diverse non-cardiac drugs, cardio-safety experts focused their attention on security measures to improve survival rates in heart stoppages due to prescribed drugs (Inchauspe, 2010a). Considering that prolongation of the QTc is a reliable marker of a menacing arrhythmia called torsade de pointes (TdP) – that can progress to ventricular fibrillation, application of Bazett, or Rautaharju formulas can lead to a proper predictive valuation of a “torsadogenic risk.” Case-analysis raises up the proposal that QTc or QTp will allow to identify high risk groups; performs a close pharmaco-vigilance and legally register ECG follow-up, avoiding unnecessary withdrawal of useful drugs from market.

**INTRODUCTION**

Sudden unexpected deaths from heart arrest have been reported with use of non-cardiac drugs since the early 1960s (Iyer, 2010). These drugs, which cause sudden death, have centered on torsade de pointes (TdP), a polymorphic ventricular arrhythmia that can progress to ventricular fibrillation and sudden death. Prolongation of the QTc interval is a surrogate marker for the ability of a drug to cause TdP. In individual patients an absolute QTc interval of $> 500$ ms or an increase of 60 ms from baseline is regarded as indicating an increased risk of TdP. However, TdP can occur with lower QTc values or changes. Concern about a relationship between QTc prolongation, TdP, and sudden death applies to a wide range of drugs and has led to the withdrawal or restricted labeling of several. Arrhythmias are more likely to occur if drug-induced QTc prolongation coexists with other risk factors, such as individual susceptibility, presence of congenital long QT syndromes, heart failure, bradycardia, electrolyte imbalance, overdose of a QTc-prolonging drug, female sex, restraint, old age, hepatic or renal impairment, and slow metabolic status. Pharmacodynamic and pharmaco-kinetic interactions can also increase the risk of arrhythmias. The risk should be viewed in the context of the overall risks and benefits of anticancer treatment. It seems prudent, where possible, to select anticancer treatments that are not associated with marked QTc prolongation. If use of a QTc-prolonging drug is warranted, then measures to reduce the risk should be adopted.

1-Asparaginase is marketed as a drug for the treatment of acute lymphoblastic leukemia. The main side effect is an allergic or hypersensitivity reaction; anaphylaxis is a possibility. No cardiac arrest effect has been observed before. However, in our clinical practice, a heart arrest was observed in a 1-year-old infant with leukemia.

**EXAMPLE CASE**

A male 1-year-old infant with Lymphatic acute leukemia was admitted in Hospital de Niños “Sor María Ludovica,” in La Plata, Buenos Aires, Argentina. He received the following treatment:

**Therapeutic protocol**: IB protocol, MARMA Interfant-05

- Vincristine: 0.6 mg (push)
- Daunorubicin: 12 mg/kg
- 1-Asparaginase: 1000 U.I.

Particularly, after intravenously administering 1-Asparaginase at the Hematology Ward, at 12:30 h the patient suffered cardiorespiratory arrest. Basic and advanced CPR techniques were initiated – endotracheal intubation and ambus ventilation, plus two doses of adrenaline and continued until the patient entered the Critical Care Unit about half an hour later. He presented hemodynamic decompensation (**Table 1**), hypothermia, and poor peripheral perfusion.

**MATERIALS AND METHODS**

Before a suspected diagnosis of an ANAPHYLACTIC OR IDIOSCRATIC REACTION for this cardiac arrest, the child was treated as follows:

- Basic and Advanced CPR (ILCOR) protocol
- Adrenaline (two doses).

Endotracheal intubation: respiratory Mechanical Assistance (RMA)

**Setting**: 1/fr = 22/VT 90/0.7 ri

VCV Mode: I:E = 1:2.8.

**Intravenous medications**:

- H.P.: 60/2/1
- Colloid expansion: 10 mg/Kg
- Fentanyl: 1 gamma/kg/h
- Midazolam: 0.1 mg/kg/h
Inchauspe Torsadogenic index

Hematological treatment:

K vitamin: 5 mg/dose/day.

After indicating the inotropic support and the volemia expansion by means of crystalloids, laboratory results were received. They confirmed hemostasis alteration, which is corrected by providing K vitamin (see Table 2).

RESULTS

Fortunately, this kid had a favorable evolution, as we can see in his tests controls (see Table 3).

In Figure 1, an ECG sample performed a day after the emergency is shown. It features a frequency of almost 200/min and P wave absence (only catching the last four beats), most presumably due to an inotropic effect.

Cardiac toxicity from these drugs is reported in Goodman–Gilman’s Treatise.

Individual idiosyncratic potential risk increases this danger in the whole of the protocol products (Litchner, 2010). Among them, both Vincristine and l-Asparaginase cause severe hepatotoxicity, derived from their pharmaco-kinetic metabolism, as was shown in the hemostasis defect.

The new decision of spreading the infusions of the protocol drugs within the week was made in order to allow the liver to recover (Swedborg, 2010).

The condition regressed completely at night (around 9:00 pm), and control parameters came back to normal (see Table 2).

DISCUSSION

Currently, there are many products that can induce QT-interval prolongation at the ECG, thus favoring sudden death (Inchauspe, 2010b).

WHO defines Sudden Death as an episode appearing within 24 h of the beginning of an illness.

Under both eastern and western concepts, the combinations proposed in some protocols (and others enlisted by Dr. Wang (Wang, 2010) in the Harvard Office of Toxicology Exploration) could lead to a disruption of the ionic potassium channels of the myocardial cells (Asai, 2010), mostly in patients with congenital or acquired Long QT Syndrome. This condition could give rise to the appearance of precocious post-depolarizations (PDPs). Once they have reached a threshold amplitude, the PDPs can trigger highly risky arrhythmia known as “Torsade de pointes” (Dessertenne, 1966; Dessertenne et al., 1966), and a possible cardiac arrest.

Fortunately, today there is the possibility of carrying out ambulatory studies of cardiac frequency variability through continuous monitoring of spectral analysis of R–R’ (Inchauspe, 2011), corrected QT formulas are still a very practical way to determine QT-interval length next to the patient’s bed:

Application of QTc (corrected) Bazett Formula:

\[
QT(c) = \frac{QT}{\sqrt{R - R’}}
\]

or QTp (precision) Rautaharhu Formula:

\[
QT(p) = \frac{656}{1 + \frac{\text{cardiac rate}}{100}}
\]

Both formulas are appropriate as a QT screening since values over 0.45 s will be indicative of a QT-interval prolongation. And rates over 0.66 s would be likely to pose a torsadogenic risk (Lanzotti and Citta, 2003).

Proposal of a QTc or QTp screening will allow us to:

(a) Identify high risk groups;
(b) Perform close pharmaco-vigilance during treatment;

---

**Table 1 | Parameters I: hemodynamic decompensation.**

| Parameter                  | Value           |
|----------------------------|-----------------|
| Cardiac frequency          | 160/min         |
| TA                         | 48/32 mm Hg     |
| O₂ sat.                    | 100%            |
| T’                         | 36°C (hypothermia – coldness in distal extremities) |
| Peripheral perfusion       | Capillary repletion > 3 s |
| Photomotor reflex          | Isocoria – reactive pupillary reflex |

**Table 2 | Parameters II: hemostase impairment.**

| Parameter          | Value       |
|--------------------|-------------|
| Prothrombin conc.  | 52%         |
| KPTT               | 18.4 s      |
| Partial thromboplastin time | 86 s |

**Table 3 | Parameters III: recovery.**

| Parameter       | Value           |
|-----------------|-----------------|
| Cardiac rate    | 140/min         |
| TA              | 82/55 mm Hg     |
| O₂ sat.         | 100%            |
| Respiratory rate| 22/min          |
| Peripheral pulses | Present       |

---

**FIGURE 1 | ECG sample performed 24 hours after the emergency.**
(c) Legally register ECG follow-up (useful as medical responsibility evidence);
(d) Avoid the unnecessary withdrawal of essential drugs from the market.

Each year 1,500,000 patients severely injured by prescribed drugs require hospitalization.

Out of these, 100,000 die, this being the fourth cause of death in USA.

REFERENCES
Asai, Y. (2010). “Direct measurement of the QT interval in the stem cell derived cardiomyocytes for the assessment of QT liability,” in BIT’s 8th Annual Congress of International Drug Discovery Science and Technology, Beijing.
Dessertenne, F. (1966). La tachicardie ventriculaire a deux foyers opposes variables. Arch. Mal. Coeur. Vaiss. 59, 263–272.
Dessertenne, F., Fabiato, A., and Courmel, P. (1966). Un chapitre nouveau de électrocardiographie: Les variations progressives de l’amplitude de l’électrocardiogramme. Actual Cardio. Angio. Int. 15, 241–258.
Inchauspe, A. (2010a). Traditional Chinese medicine K-1 Yongquan and resuscitation: another kind of Lazarus Phenomenon. Resuscitation 81, 505–506.
Inchauspe, A. (2010b). “D-Phenylalanine injection over K-1 Yongquan: a theoretical way of upgrading survival rates in CPR,” in Bit’s 8th Annual Congress of International Drug Discovery Science and Technology (IDDST), Chap. 7, Sect. 7, Beijing.
Inchauspe, A. (2011). Farmacovigilancia y Muerte Súbita. La Plata: Jornadas Multidisciplinarias del Hospital.
Iyer, D. (2010). “Optimum patient care through appropriate drug safety monitoring,” in BIT’s 8th Annual Congress of International Drug Discovery Science and Technology (IDDST), Chap. 1, Sect. 1, Beijing.
Lanzotti, M., and Citta, N. (2003). Síndrome de QT largo Adquirido: Torsade de pointes. Buenos Aires: Università degli Studi dell’Insubria.
Litchner, R. (2010). “Explorative toxicological assessment of consumer products,” in BIT’s 8th annual Congress of International Drug Discovery Science and Technology (IDDST), Chap. 1, Sect. 1, Beijing.
Swedborg, N. (2010). “Drug abuse and dependence liability assessment in safety pharmacology,” in BIT’s 8th Annual Congress of International Drug Discovery Science and Technology (IDDST), Chap. 1, Sect. 1, Beijing.
Wang, J. (2010). “Cardiovascular safety: how to develop risk assessment,” in BIT’s 8th Annual Congress of International Drug Discovery Science and Technology (IDDST), Chap. 1, Sect. 1, Beijing.

Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 16 February 2012; paper pending published: 06 March 2012; accepted: 04 May 2012; published online: 14 June 2012.

Citation: Inchauspe AA (2012) Torsadogenic index: a proposal to improve survival rates in cardiac arrests due to prescribed drugs. Front. Pharmacol. 3:99. doi: 10.3389/fphar.2012.00099

This article was submitted to Frontiers in Pharmaceutical Medicine and Outcomes Research, a specialty of Frontiers in Pharmacology.

Copyright © 2012 Inchauspe. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.